Regenxbio (RGNX) came out with quarterly earnings of $0.12 per share, missing the Zacks Consensus Estimate of $0.41 per share. This compares to loss of $1.38 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -70.73%. A quarter ago, it was expected that this biotechnology company would post a loss of $1.27 per share when it actually produced a loss of $1.01, delivering a surprise of 20.47%.Over the last four quarters, the company ...

Rapid7 (RPD) came out with quarterly earnings of $0.49 per share, beating the Zacks Consensus Estimate of $0.35 per share. This compares to earnings of $0.55 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 40%. A quarter ago, it was expected that this cybersecurity company would post earnings of $0.50 per share when it actually produced earnings of $0.48, delivering a surprise of -4%.Over the last four quarters, the company ha ...

Runway Growth Finance Corp. (RWAY) came out with quarterly earnings of $0.42 per share, beating the Zacks Consensus Estimate of $0.36 per share. This compares to earnings of $0.46 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 16.67%. A quarter ago, it was expected that this company would post earnings of $0.42 per share when it actually produced earnings of $0.39, delivering a surprise of -7.14%.Over the last four quarters, ...

Stellus Capital (SCM) came out with quarterly earnings of $0.37 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.44 per share a year ago. These figures are adjusted for non-recurring items.A quarter ago, it was expected that this investment company would post earnings of $0.38 per share when it actually produced earnings of $0.37, delivering a surprise of -2.63%.Over the last four quarters, the company has surpassed consensus EPS estimates just once.Stellus Capital, whic ...

Energy Vault Holdings, Inc. (NRGV) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to loss of $0.14 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 38.46%. A quarter ago, it was expected that this company would post a loss of $0.14 per share when it actually produced a loss of $0.35, delivering a surprise of -150%.Over the last four quarters, the company h ...

ZoomInfo (ZI) came out with quarterly earnings of $0.23 per share, beating the Zacks Consensus Estimate of $0.22 per share. This compares to earnings of $0.26 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 4.55%. A quarter ago, it was expected that this company would post earnings of $0.23 per share when it actually produced earnings of $0.26, delivering a surprise of 13.04%.Over the last four quarters, the company has surpas ...

Company Performance - TPI Composites reported a quarterly loss of $1.01 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.50, representing an earnings surprise of -102% [1] - The company posted revenues of $336.16 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 7.39%, compared to revenues of $299.06 million a year ago [2] - Over the last four quarters, TPI Composites has not surpassed consensus EPS estimates and has topped consensus revenue estimates two times [2] Stock Outlook - TPI Composites shares have declined approximately 54% since the beginning of the year, while the S&P 500 has decreased by -3.8% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.34 on revenues of $367.33 million, and for the current fiscal year, it is -$1.92 on revenues of $1.42 billion [7] Industry Context - The Industrial Services industry, to which TPI Composites belongs, is currently ranked in the bottom 37% of over 250 Zacks industries, indicating a challenging environment [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact TPI Composites' stock performance [5][6]

Core Insights - Simon Property (SPG) reported $1.47 billion in revenue for Q1 2025, a year-over-year increase of 2.1% [1] - The EPS for the same period was $2.95, compared to $2.25 a year ago, indicating a positive growth trend [1] - The reported revenue was slightly below the Zacks Consensus Estimate of $1.48 billion, resulting in a revenue surprise of -0.67% [1] - The EPS exceeded the consensus estimate of $2.91, leading to an EPS surprise of +1.37% [1] Financial Metrics - Occupancy rate for U.S. Malls and Premium Outlets was 95.9%, slightly below the three-analyst average estimate of 96.5% [4] - Revenue from management fees and other revenues was $33.79 million, surpassing the estimated $31.10 million, reflecting a year-over-year increase of +14.7% [4] - Lease income revenue was $1.37 billion, slightly above the estimated $1.35 billion, showing a +5% change compared to the previous year [4] - Other income revenue was $71.79 million, significantly below the estimated $98.36 million, representing a decline of -35% year-over-year [4] - Net Earnings Per Share (Diluted) was $1.27, lower than the average estimate of $1.46 [4] Stock Performance - Simon Property shares have returned +10.1% over the past month, outperforming the Zacks S&P 500 composite's +3.8% change [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]

For the quarter ended March 2025, Aquestive Therapeutics (AQST) reported revenue of $8.72 million, down 27.6% over the same period last year. EPS came in at -$0.24, compared to -$0.17 in the year-ago quarter.The reported revenue represents a surprise of -28.14% over the Zacks Consensus Estimate of $12.14 million. With the consensus EPS estimate being -$0.17, the EPS surprise was -41.18%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations ...

Coherus BioSciences (CHRS) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to loss of $0.32 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -12.90%. A quarter ago, it was expected that this drug developer would post a loss of $0.23 per share when it actually produced a loss of $0.28, delivering a surprise of -21.74%.Over the last four quarters, the company ...